AstraZeneca and Incyte are about to enter into Clinical Trial Collaboration in Early Lung Cancer
The exclusive collaboration for the study population allows the two companies to conduct a Phase 3 trial. Aim of this study is to evaluate patients with locally-advanced (Stage III), unresectable non-small cell lung cancer (NSCLC), whose disease has not progressed following platinum-based chemotherapy concurrent with radiation therapy (CRT).
Tocagen’s combo therapy enters directly into phase 3 trials after getting approval from FDA
Tocagen is moving directly into a phase 3 trial with its combo therapy Toca 511 and Toca FC gene therapy in cancer and thus needs more pa...
